The global cell counting market size reached USD 13.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 24.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.82% during 2025-2033. The market is driven by the increasing prevalence of chronic diseases, significant advancements in cell counting technologies, and the growing demand for personalized medicine. Extensive research and development (R&D) activities in the field of biotechnology and pharmaceuticals are further contributing to the market growth significantly.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 13.2 Billion |
Market Forecast in 2033
|
USD 24.6 Billion |
Market Growth Rate 2025-2033 | 6.82% |
Significant Advancements in Biotechnology
Rapid advancements in biotechnology, along with innovations, including the development of high-throughput cell counters and advanced flow cytometry techniques, which are significantly driving the cell counting market. For instance, in May 2023, Sysmex Corporation introduced XF-1600, a clinical flow cytometry solution, along with the PS-10 sample preparation system, antibody reagents, and related products in Japan. This launch aimed to improve testing efficiency and standardization, allowing clinical technologists to focus on more complex analyses while strengthening Sysmex's market position. These technological advancements enable precise and rapid analysis of cell populations, enhancing research efficiency and clinical diagnostics. Additionally, improved automation and data integration capabilities contribute to more accurate and streamlined cell counting processes, meeting the needs of both research and healthcare sectors.
Increasing Prevalence of Chronic Diseases
The cell counting demand and need is increasing due to growing incidence of chronic diseases, such as cancer, diabetes, HIV, and cardiovascular disorders. Cell counting is essential for disease diagnosis, treatment monitoring, and research. According to the WHO, HIV remains a significant global public health issue, with an estimated 42.3 million lives lost to date. Transmission continues worldwide, and by the end of 2023, approximately 39.9 million people were living with HIV. In 2023, an estimated 630,000 people died from HIV-related causes, and about 1.3 million people acquired the virus. Accurate cell analysis is crucial for understanding disease progression and evaluating therapeutic responses, which, in turn, drives the need for advanced cell counting technologies in clinical and research laboratories.
Expansion of Research and Development Activities
According to the cell counting market overview, the market growth is significantly driven by an increase in research and development activities across various fields, including pharmaceuticals, biotechnology, and cell biology. Enhanced funding and emphasis on cell-based research and drug development necessitate advanced cell counting solutions to support experiments and clinical trials. This growth stimulates the demand for sophisticated cell counting instruments that provide high accuracy, reproducibility, and efficiency in research applications. For instance, in August 2023, Abbott Laboratories received approval from the US FDA for its Alinity h-series hematology system. This approval enables Abbott to strengthen its diagnostics business. Such approvals from significant regulatory bodies prove critical for the market growth, which, in turn, aids in creating a positive cell counting market outlook.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on product type and end user.
Breakup by Product Type:
Consumables accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the product type. This includes consumables (reagents, assay kits, microplates, and accessories) and instruments (spectrophotometers, flow cytometers, hematology analyzers, and cell counters). According to the report, consumables represented the largest segment.
According to the cell counting market report, the consumables segment is expected to experience significant expansion due to their recurrent use in laboratory procedures, which ensures a steady demand. These items are essential for the preparation, analysis, and maintenance of cell samples. Unlike durable equipment, consumables need regular replenishment, driving continuous sales. Furthermore, advancements in cell counting technologies and the increasing complexity of research and clinical diagnostics require high-quality, specialized consumables. Their critical role in ensuring accurate, reproducible results makes them indispensable in both research and clinical settings, thereby propelling their market dominance. For instance, in October 2023, F. Hoffmann-La Roche Ltd announced a partnership with Ibex Medical Analytics, an Israeli biotech firm, and Amazon Web Services (AWS) to integrate Roche’s Navify Digital Pathology software with Ibex’s AI-driven decision support tools. This collaboration allows pathologists using the Navify platform to securely access Ibex’s third-party AI technologies alongside Roche’s expanding array of AI-based image analysis tools, thereby enhancing clinical workflow efficiency.
Breakup by End User:
Research and academic institutes hold the largest share of the industry
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and diagnostic laboratories, research and academic institutes, pharmaceutical and biotechnology companies, and others. According to the report, research and academic institutes accounted for the largest market share.
Research and academic institutes hold the largest share of cell counting market revenue primarily due to their significant role in advancing biomedical research, disease diagnosis, and therapeutic development. These institutions continuously conduct extensive studies that require precise cell counting to understand cellular behaviors, develop new treatments, and validate experimental outcomes. Additionally, the growing emphasis on life sciences and biotechnology education has led to increased funding and resources, further driving the demand for cell counting technologies. The integration of advanced technologies and collaborations with industry also enhance their capacity to perform high-throughput and accurate cell analysis, solidifying their dominant market position. One of the recent cell counting market recent developments includes a collaboration announced in June 2023 between OGT, a subsidiary of Sysmex Corporation, and Applied Spectral Imaging (ASI), a leader in advanced biomedical imaging solutions. Through this partnership, OGT obtained the marketing rights for ASI’s unique cytogenetic imaging and analysis technologies. This alliance aims to enhance clinical laboratories' ability to perform comprehensive genomic structural measurements.
Breakup by Region:
North America leads the market, accounting for the largest cell counting market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for cell counting.
The North American region boasts advanced healthcare infrastructure, extensive research and development activities, and significant investments in biotechnology and pharmaceutical industries. For instance, in 2023, U.S. healthcare spending increased by 7.5%, reaching $4.8 trillion, which outpaces the projected annual GDP growth rate of 6.1%. Additionally, the presence of leading market players and a high adoption rate of innovative technologies contribute to market dominance. Robust funding from government and private sectors for research, coupled with favorable regulatory frameworks, further enhances market growth. Moreover, according to the cell counting market forecast, the increasing prevalence of chronic diseases and a steadily rising elderly population base are expected to drive the demand for precise cell counting techniques, solidifying North America's leading position in this market. According to American Cancer Society, breast cancer is the most common cancer among women in the U.S., accounting for 30% of new female cancers each year. In 2024, an estimated 310,720 new cases of invasive breast cancer and 56,500 cases of ductal carcinoma in situ (DCIS) will be diagnosed. Cell counting methodologies are essential in cancer research for evaluating cell proliferation rates, assessing tumor progression, determining treatment responses, and analyzing cell characteristics.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Product Types Covered |
|
End Users Covered | Hospitals and Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd. (Roche Holding AG)., Merck & Co. Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: